Paul W. Manley

Basel, BS 4056, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Clinical Pharmacology of Asciminib: A Review.

Clinical Pharmacology of Asciminib: A Review.

Journal: Clinical pharmacokinetics

Published: September 06, 2024

Evidence supporting that the attribution of first success in use of arsenic for the treatment of leukaemia should be to David Lissauer (1836-1892).

Evidence supporting that the attribution of first success in use of arsenic for the treatment of leukaemia should be to David Lissauer (1836-1892).

Journal: Leukemia

Published: April 22, 2022

BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma.

BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma.

Journal: Blood cancer journal

Published: March 31, 2022

In Vivo Evaluation of Fibroblast Growth Factor Receptor Inhibition in Mouse Xenograft Models of Gastrointestinal Stromal Tumor.

In Vivo Evaluation of Fibroblast Growth Factor Receptor Inhibition in Mouse Xenograft Models of Gastrointestinal Stromal Tumor.

Journal: Biomedicines

Published: February 15, 2022

Correspondence on "Synergy and Antagonism between Allosteric and Active-Site Inhibitors of Abl Tyrosine Kinase".

Correspondence on "Synergy and Antagonism between Allosteric and Active-Site Inhibitors of Abl Tyrosine Kinase".

Journal: Angewandte Chemie (International ed. in English)

Published: December 20, 2021

A kinase inhibitor which specifically targets the ABL myristate pocket (STAMP), but unlike asciminib crosses the blood-brain barrier.

A kinase inhibitor which specifically targets the ABL myristate pocket (STAMP), but unlike asciminib crosses the blood-brain barrier.

Journal: Bioorganic & medicinal chemistry letters

Published: September 29, 2021

Discovery of Potent, Highly Selective, and In Vivo Efficacious, Allosteric MALT1 Inhibitors by Iterative Scaffold Morphing.

Discovery of Potent, Highly Selective, and In Vivo Efficacious, Allosteric MALT1 Inhibitors by Iterative Scaffold Morphing.

Journal: Journal of medicinal chemistry

Published: November 30, 2020

The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.

The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.

Journal: Leukemia research

Published: July 16, 2020

BET bromodomain inhibitors regulate keratinocyte plasticity.

BET bromodomain inhibitors regulate keratinocyte plasticity.

Journal: Nature chemical biology

Published: September 27, 2019

Investigations into the Potential Role of Metabolites on the Anti-Leukemic Activity of Imatinib, Nilotinib and Midostaurin.

Investigations into the Potential Role of Metabolites on the Anti-Leukemic Activity of Imatinib, Nilotinib and Midostaurin.

Journal: Chimia

Published: August 22, 2019

Correction: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.

Correction: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.

Journal: British journal of cancer

Published: June 21, 2019

Tyrosine kinase inhibitors relax pulmonary arteries in human and murine precision-cut lung slices.

Tyrosine kinase inhibitors relax pulmonary arteries in human and murine precision-cut lung slices.

Journal: Respiratory research

Published: October 20, 2018

Showing 1-12 of 41

Last Updated: 09/26/2026